Viridian Therapeutics
VRDN
VRDN
31 hedge funds and large institutions have $57.4M invested in Viridian Therapeutics in 2017 Q2 according to their latest regulatory filings, with 20 funds opening new positions, 8 increasing their positions, 1 reducing their positions, and 5 closing their positions.
New
Increased
Maintained
Reduced
Closed
more repeat investments, than reductions
Existing positions increased: | Existing positions reduced:
more first-time investments, than exits
New positions opened: | Existing positions closed:
more funds holding
Funds holding: →
more capital invested
Capital invested by funds: $ → $
0.29% more ownership
Funds ownership: 1.09% → 1.38% (+0.29%)
Holders
31
Holding in Top 10
1
Calls
–
Puts
–
Top Buyers
| 1 | +$6.67M | |
| 2 | +$1.54M | |
| 3 | +$1.37M | |
| 4 |
Goldman Sachs
New York
|
+$742K |
| 5 |
TCIM
TIAA CREF Investment Management
New York
|
+$455K |
Top Sellers
| 1 | -$811K | |
| 2 | -$498K | |
| 3 | -$347K | |
| 4 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$177K |
| 5 |
SCM
Segantii Capital Management
Hong Kong
|
-$77K |